Androgen Reduction in Congenital Adrenal Hyperplasia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2023-01-31

Study Completion Date

2026-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Children with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency tend to have elevated circulating levels of androgens, which can accelerate skeletal maturation and adversely impact adult height. Additionally, these children require supraphysiologic doses of hydrocortisone to suppress secretion of adrenal androgen precursors, and this treatment can retard linear growth. This study seeks to use oral abiraterone acetate (Zytiga)as an adjunct to approved CAH therapy (oral hydrocortisone and fludrocortisone) for pre-pubescent children with classic 21-hydroxylase deficiency in order to reduce daily requirement of hydrocortisone.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1

NCT02574910

Congenital Adrenal Hyperplasia

TERMINATED PHASE1

Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia

NCT00001521

Congenital Adrenal Hyperplasia (CAH)

COMPLETED PHASE3

Subcutaneous Hydrocortisone Children With Congenital Adrenal Hyperplasia

NCT03718234

Congenital Adrenal Hyperplasia Hyperplasia Adrenal Hyperplasia +8 more

COMPLETED PHASE1

Natural History Study of Patients With Excess Androgen

NCT00250159

Congenital Adrenal Hyperplasia (CAH) Familial Male-Limited Precocious Puberty (FMPP)

RECRUITING

Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia

NCT01859312

Adrenal Insufficiency Excess Androgen Congenital Adrenal Hyperplasia (CAH)

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Congenital adrenal hyperplasia (CAH) is an inherited inability to synthesize cortisol in the adrenal gland. More than 90% of cases are cause by deficiency of steroid 21-hydroxylase (CYP21, also termed CYP21A2, P450c21), which is a cytochrome P450 enzyme located in the endoplasmic reticulum. It catalyzes conversion of 17-hydroxyprogesterone (17-OHP) to 11-deoxycortisol, a precursor for cortisol, and progesterone to deoxycorticosterone, a precursor for aldosterone. Aldosterone deficiency may lead to salt wasting with consequent failure to thrive, hypovolemia, shock and if untreated, death in the first few weeks of life. Because patients cannot synthesize cortisol efficiently, the adrenal cortex is stimulated by corticotropin (ACTH) and overproduces cortisol precursors. Some of these precursors are diverted to sex hormone biosynthesis, which may cause signs of androgen excess including ambiguous genitalia in newborn females, rapid postnatal growth in both sexes, and accelerated skeletal maturation and decreased adult height. Patients require supraphysiologic replacement doses of glucocorticoids to suppress the adrenocorticotropic hormone (ACTH)-driven adrenal androgen synthesis. Excessive glucocorticoids are associated with excessive weight gain and slowing of linear growth. It would be desirable in pre-pubertal children to decrease the exposure to excess glucocorticoids while avoiding the adverse effects of inappropriate exposure to androgens. Abiraterone acetate is a prodrug of abiraterone, an irreversible inhibitor of 17α hydroxylase/C17, 20-lyase (cytochrome P450c17 \[CYP17\]), a key enzyme required for testosterone synthesis. This agent indeed suppresses adrenal androgen secretion in adult women. This Phase 2 will determine if, over 24 months, this treatment retards bone age advancement and thus improves adult height prognosis. The present study is the first clinical trial to explore the utility of abiraterone acetate as a means for decreasing daily requirements for glucocorticoids in pre-pubertal children with 21-hydroxylase deficiency.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Congenital Adrenal Hyperplasia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Daily placebo, plus usual maintenance treatment with hydrocortisone and fludrocortisone.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Daily placebo for 2 years.

Hydrocortisone

Intervention Type DRUG

Hydrocortisone will be administered at a starting dose of 7-9 mg/M2/d and adjusted as necessary based on 17-hydroxyprogesterone and ACTH levels.

Fludrocortisone

Intervention Type DRUG

Fludrocortisone will be administered at the dose the subject was taking a study entry and adjusted as necessary to keep plasma renin in the high normal range.

Abiraterone acetate

Abiraterone acetate administered daily in dose determined in Phase 1, plus usual maintenance treatment with hydrocortisone and fludrocortisone..

Group Type EXPERIMENTAL

Abiraterone acetate

Intervention Type DRUG

Daily oral abiraterone acetate for 2 years. The dose will be specified based on pharmacodynamic data from Phase 1.

Hydrocortisone

Intervention Type DRUG

Hydrocortisone will be administered at a starting dose of 7-9 mg/M2/d and adjusted as necessary based on 17-hydroxyprogesterone and ACTH levels.

Fludrocortisone

Intervention Type DRUG

Fludrocortisone will be administered at the dose the subject was taking a study entry and adjusted as necessary to keep plasma renin in the high normal range.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Abiraterone acetate

Daily oral abiraterone acetate for 2 years. The dose will be specified based on pharmacodynamic data from Phase 1.

Intervention Type DRUG

Placebo

Daily placebo for 2 years.

Intervention Type DRUG

Hydrocortisone

Hydrocortisone will be administered at a starting dose of 7-9 mg/M2/d and adjusted as necessary based on 17-hydroxyprogesterone and ACTH levels.

Intervention Type DRUG

Fludrocortisone

Fludrocortisone will be administered at the dose the subject was taking a study entry and adjusted as necessary to keep plasma renin in the high normal range.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Zytiga

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pre-pubescent girls (age 2 years \[12 kg\] to 8 years inclusive; skeletal age ≤9 years) or boys (age 2 years \[12 kg\] to 9 years inclusive; skeletal age ≤10 years).
* Confirmed classic 21-hydroxylase deficiency evident by genotype groups A, A1 or B, or by clinical course.
* Requirement for standard of care fludrocortisone (any dose) and ≥10 mg/m2/day of hydrocortisone for at least 1 month prior to the study consent.
* Morning serum androstenedione concentrations \>1.5 x ULN after 7 days of dosing with doses of hydrocortisone required for physiologic replacement.
* Informed consent .

Exclusion Criteria

* Evidence of central puberty: Tanner Stage \>2 for breast development in girls or testicular volume \>4 mL in boys, or random LH \>0.3 mIU/mL.
* Current or history of hepatitis from any etiology.
* Abnormal liver function tests (transaminases\>3X ULN).
* Abnormal renal function tests (BUN or creatinine \>1.5 ULN).
* Significant anemia (hemoglobin \< 12 g/dl).
* Clinically significant ECG abnormality
* A history of a malabsorption syndrome.
* Evidence of active malignancy.
* Co-existent disease that may interfere with linear growth or that requires concomitant therapy that is likely to interfere with study procedures or results.
* Treatment with potentially hepatotoxic medications, CYP2D6, strong inhibitors or inducers of CYP3A4
* Treatment with medications to affect puberty or synthesis of sex steroids, including gonadotropin releasing hormone agonists, aromatase inhibitors, or androgen receptor blockers
* Treatment with growth hormone
* Known allergies, hypersensitivity, or intolerance to abiraterone acetate or its excipients.

Minimum Eligible Age

2 Years

Maximum Eligible Age

9 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No